Study Aims to Identify Women with Ovarian Cancer Who May Benefit from Maintenance Treatment

Study Aims to Identify Women with Ovarian Cancer Who May Benefit from Maintenance Treatment
Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab). Myriad’s myChoice HRD Plus is a test for BRCA1 and BRCA2 tumor status, as well as tumor genomic instability status – the frequency at

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *